AMR Accelerator

Few researchers and organisations have the expertise, skills, and infrastructure to tackle #AMR and discover new #antibiotics. Long-term funding for #antibiotic development partnerships will help attract young scientists to the field and keep companies in anti-infective drug development. To secure a sustainable future for efforts of this scale, we call on government leaders, the private sector and other stakeholders to invest in the development of antibiotics and AMR research.   The AMR Accelerator is an Innovative Health Initiative (IHI) programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building #antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of our assets, infrastructures and expertise. Read more in our article: https://lnkd.in/eqGbRqmg Explore our results: https://lnkd.in/ebSUbVhB

𝗔𝗻𝗼𝘁𝗵𝗲𝗿 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 ERA4TB 𝗖𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺! 🎉 New research paper published on implementing best practices on data generation and reporting of Mycobacterium tuberculosis 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 assays. 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗣𝗮𝗽𝗲𝗿 📜 For those interested in exploring the full research, it is available here: 🔗 https://lnkd.in/g5-ViTNq This publication represents another step towards understanding how the collaboration between partners in an IMI consortium can be further harmonized to implement and standardize experimental protocols and data management for consistent reporting and sharing within the AMR Accelerator program. 👉 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂𝗿 𝗹𝗼𝘃𝗲 & 𝘀𝘂𝗽𝗽𝗼𝗿𝘁! 𝗟𝗶𝗸𝗲 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝘁𝗵𝗼𝘀𝗲 𝘄𝗵𝗼 𝗺𝗮𝘆 𝗳𝗶𝗻𝗱 𝗶𝘁 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹! #AMR #EndTB #MedicalResearch #HealthcareInnovation Innovative Health Initiative (IHI) ERA4TB RespiriNTM RespiriTB BioVersys AG UNITE4TB

𝗬𝗲𝘀! 𝗪𝗲 𝗖𝗮𝗻 𝗘𝗻𝗱 𝗧𝗕: 𝗖𝗼𝗺𝗺𝗶𝘁, 𝗜𝗻𝘃𝗲𝘀𝘁, 𝗗𝗲𝗹𝗶𝘃𝗲𝗿. This year’s World Health Organization theme is a strong call for optimism, action and responsibility, and we at AMR Accelearator are inspired! Join us for our next webinar with health economics experts to examine TB's global cost burden on health systems and patients. 𝗪𝗲 𝘄𝗶𝗹𝗹 𝗰𝗼𝘃𝗲𝗿: ✔️The range of costs associated with TB ✔️How we measure these ✔️Role of health economics into the priorities for new TB treatment development. 𝗔 𝗠𝘂𝘀𝘁-𝗔𝘁𝘁𝗲𝗻𝗱 𝗳𝗼𝗿: 🔬 People working in TB or antimicrobial drug development. 📉 Individuals interested in the health economics of TB, including health technology assessment agencies. 🌟 Anyone enthusiastic about advancing the field. Hosted by ERA4TB and COMBINE, this is a first of 3-part webinar series focused on health economics and TB. 👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝗮𝘁 https://lnkd.in/dcW_6fKj Follow us along to explore more in detail about the critical issues surrounding TB! #AMR #webinar #TB #Healtheconomics Innovative Health Initiative (IHI)

As part of International Women’s Day, we asked consortium members from across the ERA4TB workstreams to tell us why they feel it is important for women to be involved in TB research. We also asked them what they would like to see happen in the world to #AccelerateAction – on advancing and celebrating women’s equality worldwide. You can read here some of the highlights of what they told us, and over the next few days, we will be sharing the longer interviews so you can find out more. Gilla Kaplan one of our Scientific Advisory Board members gave the following advice to women scientists: “If you go into TB research, success will clearly require hard work, technical skill and a talent to overcome all the potential difficulties encountered along the research path. However, impact on the epidemic will require being part of a research team that has the capacity to remain focused and work together to deliver on the goals undertaken. Be the passionate and collaborative researcher you know it will take to help TB patients and the communities they are part of.” A big thank you to everyone who took part in the campaign! Anna Upton, Deborah Recchia, Ainhoa Lucía Quintana, Lara V., Christine Roubert, Hala Mansour, Evotec, Università di Pavia, Institut Pasteur de Lille, Charles III University of Madrid, Universidad de Zaragoza, GSK, Institut Pasteur, AMR Accelerator, Innovative Health Initiative (IHI), SYNAPSE Research Management Partners #IWD #AccelerateAction #TBResearch

First time in many years an increase had been reported in the number of people affected with TB, among which 450 000 new cases of rifampicin-resistant TB were confirmed between 2020-21. ⚠️ 𝗜𝘀𝘀𝘂𝗲𝘀 𝘄𝗶𝘁𝗵 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗿𝗲𝗴𝗶𝗺𝗲𝗻𝘀 𝗳𝗼𝗿 𝗗𝗥-𝗧𝗕 ? - length of treatment - significant side effects - emergence of drug resistance - drug–drug interactions 💫 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀? 𝗔𝗹𝗽𝗶𝗯𝗲𝗰𝘁𝗶𝗿 (𝗕𝗩𝗟-𝗚𝗦𝗞𝟬𝟵𝟴) is the first small molecule in clinical development targeting mycobacterial transcription regulation. Alpibectir enhances the bioactivation of ethionamide (Eto) allowing for lower doses with fewer side effects, potentially transforming TB treatment. In this week’s edition we present: “𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗮𝗹𝗽𝗶𝗯𝗲𝗰𝘁𝗶𝗿 (𝗕𝗩𝗟-𝗚𝗦𝗞𝟬𝟵𝟴), 𝗮 𝗻𝗼𝘃𝗲𝗹 𝗽𝗼𝘁𝗲𝗻𝘁 𝗮𝗻𝘁𝗶-𝗧𝗕 𝗱𝗿𝘂𝗴” by Pieren et al., 2024 under TRIC-TB. 🧪 𝗠𝗮𝗷𝗼𝗿 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 ? - Reduces drug resistance concerns - Improves patient adherence with lower toxicity - Maximizes the potential of a 60-year-old drug 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿: https://lnkd.in/dWdGqaQn What are your thoughts on the future of TB treatment? Let's discuss in comments! #TB #Innovation #DrugResistance #AMR

The #PrIMAVeRa_AMR consortium celebrates the acceptance of its newly produced video 📽️ to be presented at #ESCMIDGlobal Event 2025 in Vienna! This video gives an accessible introduction to the project’s goals and methods, and includes interviews with key partners including: -       Dr. Irina Meln, PhD, Project Coordinator, of the European Vaccine Initiative (EVI) Vaccine Initiative -       Dr. Marc Bonten, Scientific Lead, of the UMC Utrecht -       Dr. Venanzio Vella, EFPIA - European Federation of Pharmaceutical Industries and Associations Lead, of GSK Vaccines 📝Read more, and view the video here: https://lnkd.in/dn5DJaGb By lowering the occurrence of infectious diseases, reducing the reliance on #antibiotics, and limiting the development of #AMR within communities, #vaccines can serve as a crucial tool in combating and managing AMR, and ultimately #savelives. --- #Eufunded #StopSuperbugs #StopSuperbugs Innovative Health Initiative (IHI), AMR Accelerator  ESCMID - European Society of Clinical Microbiology and Infectious Diseases

Last month, we took a deep dive into how our researchers developed a ML model which can help identify new antimicrobial compounds. Check out the key takeaways & watch the recording of our researchers as they discuss how the model was developed and its application to combat AMR.     👉 Watch here: https://lnkd.in/e8irM6FR 👉 Visit our website to learn more: https://lnkd.in/e8irM6FR Let us know in comments what was your biggest takeaway from our last month discussion around AI-based models in tackling AMR. #AMR #webinar #recording #ML Innovative Health Initiative (IHI) ERA4TB RespiriNTM RespiriTB UNITE4TB Lygature

Long-term care facilities are hotspots for pathogen transmission, but what if we could make infection control interventions more effective? Our research paper highlights that 𝗻𝗼𝘁 𝗮𝗹𝗹 𝗰𝗼𝗻𝘁𝗮𝗰𝘁𝘀 𝗮𝗿𝗲 𝗲𝗾𝘂𝗮𝗹. By identifying "𝘀𝘂𝗽𝗲𝗿𝗰𝗼𝗻𝘁𝗮𝗰𝘁𝗼𝗿𝘀”, among staff and patients we can significantly reduce the spread of MRSA and other nosocomial pathogens. In this week’s edition we present: “𝗨𝘀𝗶𝗻𝗴 𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝗱𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝘁𝗼 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝗶𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻𝘀 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝘀𝗽𝗿𝗲𝗮𝗱 𝗶𝗻 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝘀𝗲𝘁𝘁𝗶𝗻𝗴𝘀: 𝗔 𝗺𝗼𝗱𝗲𝗹𝗹𝗶𝗻𝗴 𝘀𝘁𝘂𝗱𝘆” by Leclerc et al., 2024. In this paper, our researchers used an individual-based model (IBM) to reproduce methicillin-resistant Staphylococcus aureus colonization transmission dynamics over a detailed contact network recorded within a French LTCF of 327 patients and 263 staff over a period of 3 months This study highlights: ✔️ 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝘀𝘂𝗽𝗲𝗿𝗰𝗼𝗻𝘁𝗮𝗰𝘁𝗼𝗿𝘀 enhanced intervention efficacy, with contact precautions reducing infection by up to 𝟮𝟬% ✔️ 𝗩𝗮𝗰𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘀𝘂𝗽𝗲𝗿𝗰𝗼𝗻𝘁𝗮𝗰𝘁𝗼𝗿𝘀 leads to an even higher 𝟮𝟯% reduction 👉 Read the complete paper at https://lnkd.in/dn9zCymE 👉 For more information visit https://lnkd.in/dgJedi8K.

Don't miss our ERA4TB colleagues from Universidad Carlos III de Madrid, who will attending #EMIM2025 taking place between 11-14 March, in Bilbao, Spain. They will be presenting a poster on "Automatic Whole Lung Segmentation Using 2.5D U-Net Approach in Mouse M. Tuberculosis Infection Model" #MolecularImaging AMR Accelerator, Innovative Health Initiative (IHI)

𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄? The phage lysin compound HY-133 has entered Phase I trials, targeting Staphylococcus aureus and MRSA. Learn more about such breakthroughs in our exclusive 𝗖𝗢𝗠𝗕𝗜𝗡𝗘 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 featuring three leading experts presenting 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝘀𝘁𝗼𝗿𝗶𝗲𝘀 𝗶𝗻 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 on novel antibiotics and innovative antibacterial approaches. 📅 𝗠𝗮𝗿𝗰𝗵 𝟱, 𝟮𝟬𝟮𝟱 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆 🕒 𝟭𝟱:𝟬𝟬-𝟭𝟲:𝟯𝟬 𝗖𝗘𝗧 HY-133 shows promise, but challenges like safety, delivery and resistance still remain. What in your opinion are the challenges to advancing phage lysins? Share in comments and join our webinar to discuss. 👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄: https://lnkd.in/dWbHqWwX #AMR #webinar #MDR Innovative Health Initiative (IHI)